BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired ...

Fintel reports that on November 18, 2024, BTIG initiated coverage of VYNE Therapeutics (NasdaqCM:VYNE) with a Buy ...

BTIG raised the firm’s price target on Syndax (SNDX) to $43 from $35 and keeps a Buy rating on the shares. The firm cites the company having ...

Shares of Core Scientific, Inc. (NASDAQ:CORZ – Get Free Report) have earned an average recommendation of “Buy” from the ...

Donald Trump is returning to the White House without many of the guardrails of his first term. Many Never-Trump Republicans in Congress have converted or been defeated. Former economic adviser Gary ...

Catalysts Co-hosts Brad Smith and Madison Mills dive into Nvidia earnings, Trump's ongoing Cabinet selections, and Musk's ...

Finally, BTIG Research raised their price objective on Independence Realty Trust from $18.00 to $21.00 and gave the company a ...

Starbucks (SBUX) is trying to brew up a new chapter with its baristas as the coffee giant attempts a wider turnaround in its business and stock price under new CEO Brian Niccol. It has been nearly ...

“While U.S. markets remain in firm uptrends, this is not a 2016 redux, and recent signs of froth suggested caution in chasing ...

Earlier, on September 10, 2024, BTIG Research had reduced the stock from a Buy to Neutral. Scotiabank also initiated Sector Outperform rating with a price target of $4. Additionally, BTIG Research ...

Additionally, Guggenheim initiated Buy rating on December 15, 2022, with a target price of $66. BTIG Research analysts, in their report published on November 17, 2022, also initiated Buy rating for ...

President-elect Donald Trump appears to be planning to attend a SpaceX “Starship” rocket launch on Tuesday, in the latest ...